Long term use of thalidomide: Safe and effective

Indian Journal of Cancer

Volumn 44, Issue 3, 2007, Pages 108-110

  Sharma, A ^a   Raina, V ^a   Uppal, G ^a   Kumar, R ^a   Grover, J ^a  

^a INSTITUTE ROTARY CANCER HOSPITAL   (India)

Author keywords

Multiple myeloma; Relapse; Thalidomide

Indexed keywords

EID: 38949130437     PISSN: 0019509X     EISSN: None     Source Type: Journal    
DOI: 10.4103/0019-509X.38942     Document Type: Article

References (6)

1. Bataille R, Harousseau JL. Multiple myeloma. N Engl J Med 1997;336:1657-64.
2. Myeloma Trialists' Collaborative Group. Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: An overview of 6,633 patients from 27 randomized trials. J Clin Oncol 1998;16:3832-42.
3. Alexanian R, Dimopoulos M. The treatment of multiple myeloma. N Engl J Med 1994;330:484-9.
4. Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999;341:1565-71.
5. Blade J, Esteve J. Treatment approaches for relapsing and refractory multiple myeloma. Acta Oncol 2000;39:843-7.
6. Attal M, Harousseau JL, Leyvraz S, Doyen C, Hulin C, Benboubker L, et al. Maintenance treatment with Thalidomide and Pamidronate after autologous transplantation for myeloma: Second analysis of a prospective randomized study of the "Intergroue Francophone du Myelome (IFM 99 02). Hematol Jr 2005;90:17.